Proteolysis‐targeting chimeras (PROTACs) provide a powerful technique to degrade
targeted proteins utilizing the cellular ubiquitin‐proteasome system. The major concern is …

Proteolysis-targeting chimeras or PROTACs are hetero-bifunctional molecules designed to
mediate the disposal of a target protein via recruitment of the ubiquitination–proteasome …

Targeted protein degradation compounds, including molecular glues or proteolysis targeting
chimeras, are an exciting new therapeutic modality in small molecule drug discovery. This …

To address the limitation associated with degron based systems, we have developed iTAG,
a synthetic tag based on IMiDs/CELMoDs mechanism of action that improves and addresses …

The ubiquitin-proteasome pathway plays a major role in cellular protein destruction and
regulates fundamental cellular processes such as the cell cycle, cell signaling, and …

As a newly emerged technology, PROTAC (proteolysis targeting chimera) is a promising
therapeutic strategy for varieties of diseases. Unlike small molecule inhibitors, PROTACs …

Proteolysis targeting chimeras (PROTACs) represent a new class of promising therapeutic
modalities. PROTACs hijack E3 ligases and the ubiquitin-proteasome system (UPS), leading …

Targeted protein degradation attracts attention as a novel modality for drug discovery, as
well as for basic research. Various types of degrader molecules have been developed so …

The proteome contains hundreds of proteins that in theory could be excellent therapeutic
targets for the treatment of human diseases. However, many of these proteins are from …

In recent years, targeted protein degradation (TPD) of plasma membrane proteins by
hijacking the ubiquitin proteasome system (UPS) or the lysosomal pathway has emerged as …